Clinical Trials Logo

Urinary Schistosomiasis clinical trials

View clinical trials related to Urinary Schistosomiasis.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01512277 Completed - Schistosomiasis Clinical Trials

Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis

Bilhvax1a
Start date: September 1998
Phase: Phase 1
Study type: Interventional

The purpose of this clinical study is to evaluate safety and immunogenicity in adult healthy volunteers of the vaccine candidate against schistosomiasis named Bilhvax.

NCT ID: NCT01132248 Completed - Clinical trials for Urinary Schistosomiasis

Activity of Mefloquine Against Urinary Schistosomiasis

Start date: May 2010
Phase: Phase 2
Study type: Interventional

Urinary schistosomiasis is a debilitating disease in Central Africa and pregnant women are frequently suffering from this condition. Mefloquine is currently investigated as preventive treatment against malaria in pregnancy and mefloquine is also known to exert activity against schistosomiasis. The investigators want to test the hypothesis whether mefloquine may active against urinary schistosomiasis when used as preventive treatment against malaria in pregnancy.

NCT ID: NCT00870649 Completed - Clinical trials for Schistosoma Haematobium

Efficacy of Bilhvax in Association With Praziquantel for Prevention of Clinical Recurrences of Schistosoma Haematobium

Bilhvax3
Start date: February 2009
Phase: Phase 3
Study type: Interventional

Objectives:To reduce the risk of S. haematobium pathology recurrences during the three years following vaccine administration and to control the safety of this therapeutic strategy in children exposed to urinary schistosomiasis. Methodology : Phase III trial, self-contained, randomized, double blind, in two parallel groups receiving 3 injections at D0, W4, W8 and a boost at W52, one group receiving "Bilhvax", the other one placebo, in S. haematobium infected children pretreated by two doses of PZQ (at W9 and W8) Patient included : Infected school children, 6 to 9 years of age. Primary objective : To demonstrate a significant delay of recurrence of the schistosomiasis pathology in vaccine group compared to control group in the 3 years period following the first administration (between D0 and W152). Secondary objective : safety Duration : February 2009 to March 2012